Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-921352 Phase 2 Dose-Finding Study in Adult Focal Onset Seizures
2021-001433-39Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Focal onset seizure comparing NBI-921352 adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoints: Safety and tolerability of NBI-921352, Pharmacokinetics of NBI-921352 and 1 more. Started Jul 2021; status: completed.
02
Drugs
zandatrigine
03
Conditions
Focal onset seizure
Beyond the preview
Go deeper on 2021-001433-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001433-39.